Form 4: Replimune Group Officer Sells Shares Under 10b5-1 Trading Plan

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 15,881 shares of common stock at an average price of $7.50 per share under a pre-arranged trading plan.

Summary

• Konstantinos Xynos, the Chief Medical Officer of Replimune Group, Inc., reported the sale of 15,881 shares of the company's common stock on June 7, 2024.
• The sales were executed under a pre-arranged trading plan adopted on February 13, 2024, in accordance with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• The shares were sold at prices ranging from $7.50 to $7.55, resulting in a weighted average price of $7.50 per share.
• Following the transaction, Xynos continues to beneficially own 117,131 shares of Replimune's common stock, including restricted stock units.
• Xynos also holds options to acquire 266,750 shares, with 84,280 of these options currently exercisable.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale was pre-planned and the executive still holds a significant stake in the company. It's a routine transaction rather than a reflection of negative sentiment.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.
• The reporting person continues to hold a significant number of shares and options, indicating continued alignment with the company's success.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• Continued sales by insiders, even under 10b5-1 plans, could create downward pressure on the stock price if investors interpret it as a lack of confidence.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider sales are common in the biopharmaceutical industry, especially as executives manage their personal finances. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Comparing Replimune to companies like Amgen, Gilead, and Regeneron, insider trading activity is a common occurrence.
• The use of 10b5-1 trading plans is a standard practice among executives at these companies to manage their stock holdings while complying with regulations.
• The volume of shares sold by Xynos is relatively small compared to the overall trading volume of Replimune's stock.

Stakeholder Impact

• The sale could have a minor impact on shareholder sentiment, but the existence of the 10b5-1 plan should mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates